LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

Home・Aandelen Lijst・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Gesloten

SectorGezondheidszorg

28.95 -1.76

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

28.69

Max

29.04

Belangrijke statistieken
By Trading Economics
Inkomsten	23M 7.4M
Verkoop	18M 99M
EPS	0.06
Winstmarge	7.468
Werknemers	342
EBITDA	23M 11M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+1.65% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	1.4B 3.8B
Vorige openingsprijs	30.71
Vorige sluitingsprijs	28.95

Nieuwssentiment

By Acuity

45%

55%

136 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

12.42 / 14.93 Steun & Weerstand

Arcutis Biotherapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

13 dec 2025, 00:04 UTC

Acquisities, Fusies, Overnames

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6 Billion, Bloomberg Reports, Citing Sources

12 dec 2025, 16:42 UTC

Acquisities, Fusies, Overnames

FTC Sues to Block Henkel's $725 Million Deal for Liquid Nails From PE Firm -- 2nd Update

13 dec 2025, 16:48 UTC

Acquisities, Fusies, Overnames

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13 dec 2025, 08:00 UTC

Acquisities, Fusies, Overnames

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13 dec 2025, 07:00 UTC

Acquisities, Fusies, Overnames

A Chubb/AIG Deal Could Be Good for Shareholders and a Coup for Greenberg Family -- Barrons.com

13 dec 2025, 00:24 UTC

Acquisities, Fusies, Overnames

Want a Piece Of SpaceX? -- Barrons.com

12 dec 2025, 23:49 UTC

Acquisities, Fusies, Overnames

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

12 dec 2025, 22:52 UTC

Marktinformatie

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

12 dec 2025, 22:32 UTC

Winsten

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12 dec 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

12 dec 2025, 20:45 UTC

Winsten

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

12 dec 2025, 20:41 UTC

Marktinformatie

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

12 dec 2025, 20:20 UTC

Marktinformatie

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

12 dec 2025, 19:23 UTC

Winsten

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

12 dec 2025, 18:35 UTC

Acquisities, Fusies, Overnames

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

12 dec 2025, 18:33 UTC

Acquisities, Fusies, Overnames

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

12 dec 2025, 18:31 UTC

Marktinformatie

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

12 dec 2025, 17:49 UTC

Winsten

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

12 dec 2025, 17:34 UTC

Acquisities, Fusies, Overnames

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

12 dec 2025, 17:33 UTC

Acquisities, Fusies, Overnames

Orange: Closing of the Transaction Is Expected in the First Half of 2026

12 dec 2025, 17:33 UTC

Acquisities, Fusies, Overnames

Orange: Agreement Confirms the Non-Binding Agreement That Was Previously Announced Oct. 31

12 dec 2025, 17:32 UTC

Acquisities, Fusies, Overnames

Orange: MasOrange Is Spain's Leading Operator in Terms of Customer Base

12 dec 2025, 17:31 UTC

Acquisities, Fusies, Overnames

Orange to Buy the Stake for EU4.25B in Cash

12 dec 2025, 17:24 UTC

Marktinformatie

Argentina Predicts Record Wheat Crop -- Market Talk

12 dec 2025, 17:20 UTC

Marktinformatie

Winsten

Tech, Media & Telecom Roundup: Market Talk

12 dec 2025, 17:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

12 dec 2025, 17:18 UTC

Marktinformatie

Winsten

Broadcom, Oracle Investor Reactions Show High Bar for AI Cos. -- Market Talk

12 dec 2025, 17:09 UTC

Marktinformatie

Broadcom Investors Were Primed to Sell Shares -- Market Talk

12 dec 2025, 17:09 UTC

Marktinformatie

Global Equities Roundup: Market Talk

12 dec 2025, 16:47 UTC

Marktinformatie

Broadcom's Margins Expected to Narrow Due to AI Revenue -- Market Talk

Peer Vergelijking

Prijswijziging

Arcutis Biotherapeutics Inc Prognose

Koersdoel

By TipRanks

1.65% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 29.5 USD 1.65%

Hoogste 37 USD

Laagste 21 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Arcutis Biotherapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

6 ratings

Buy

Hold

Sell

Gebaseerd op 6 analisten die aandelenratings hebben gegeven aan Arcutis Biotherapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

12.42 / 14.93Steun & Weerstand

Recent bearish events outweigh bullish events.

There is one bullish event.

Sentiment

By Acuity

136 / 374 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.